Last reviewed 2026-04-19 · How we verify

CEFMINOX

Phase 2 active Small molecule

CEFMINOX is a cefminox drug. It is currently in Phase 2 development.

Cefminox works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death.

Cefminox is a third-generation cephalosporin antibiotic, a small molecule drug class. It is used to treat bacterial infections, but its specific target and approved indications are unknown. The commercial status of cefminox is unclear, and it may be patented or off-patent. As a cephalosporin, cefminox works by inhibiting bacterial cell wall synthesis, but key safety considerations and pharmacokinetic properties are unknown. Further research is needed to fully understand cefminox.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CEFMINOX
Drug class	cefminox
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like houses, and the bacterial cell wall is like the foundation. Cefminox blocks the construction of this foundation, making it impossible for the bacteria to build a strong wall and ultimately leading to their death.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CEFMINOX CI brief — competitive landscape report
CEFMINOX updates RSS · CI watch RSS

Frequently asked questions about CEFMINOX

What is CEFMINOX?

CEFMINOX is a cefminox drug.

How does CEFMINOX work?

Cefminox works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death.

What drug class is CEFMINOX in?

CEFMINOX belongs to the cefminox class. See all cefminox drugs at /class/cefminox.

What development phase is CEFMINOX in?

CEFMINOX is in Phase 2.

Drug class: All cefminox drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing